AC-203 / Accro Biosci - LARVOL DELTA

AC-203, a new drug under development by Ancheng Biotech for the treatment of EBS, has received approval from India to proceed with Phase II/III human clinical trials [Google translation] (MoneyDJ) - "Ancheng Biotech - Announcement: The company's new drug AC-203, which is under development for the treatment of simple hereditary epidermolysis bullosa (EBS), has obtained India's approval for Phase II/III human clinical trials....This experiment is expected to be completed within 3 years, but the actual schedule will be adjusted according to the implementation progress."

New P2/3 trial • Trial completion date • Dermatology